Orthogonal Clickable Iron Oxide Nanoparticle Platform for Targeting, Imaging, and On‐Demand Release

Guldris, Noelia; Gallo, Juan; García‐Hevia, Lorena; Rivas, José; Bañobre‐López, Manuel; Salonen, Laura M.

doi:10.1002/chem.201800389

Cited by 15 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). To this end, thermo-reversible Diels−Alder (DA) reactions and thermo-labile azo-linkers have been described [13,[35][36][37][38]. Among the drawbacks associated to this strategy, the possible decrease of the biological activity of the drug when covalently attached to the MNP, and the relatively high local temperatures (80-90°C) that must be reached in order to effectively break the bonds, must be taken into account.…”

Section: Caused By Bond Breakmentioning

confidence: 99%

Triggering antitumoural drug release and gene expression by magnetic hyperthermia

Moros

Idiago-López

Asín

et al. 2019

Advanced Drug Delivery Reviews

107

View full text Add to dashboard Cite

Magnetic nanoparticles (MNPs) are promising tools for a wide array of biomedical applications. One of their most outstanding properties is the ability to generate heat when exposed to alternating magnetic fields, usually exploited in magnetic hyperthermia therapy of cancer. In this contribution, we provide a critical review of the use of MNPs and magnetic hyperthermia as drug release and gene expression triggers for cancer therapy. Several strategies for the release of chemotherapeutic drugs from thermo-responsive matrices are discussed, providing representative examples of their application at different levels (from proof of concept to in vivo applications). The potential of magnetic hyperthermia to promote in situ expression of therapeutic genes using vectors that contain heat-responsive promoters is also reviewed in the context of cancer gene therapy.

show abstract

Section: Caused By Bond Breakmentioning

confidence: 99%

Triggering antitumoural drug release and gene expression by magnetic hyperthermia

Moros

Idiago-López

Asín

et al. 2019

Advanced Drug Delivery Reviews

107

View full text Add to dashboard Cite

show abstract

“…Moreover, a proof-of-concept for pyrene release by external magnetic field showed potential as a controlled drug delivery platform. 150 In 2017, biotinylated-PEG-PLGA NPs containing DOX (BPNP) improved 4T1 cellular uptake in flow cytometry compared with non-biotinylated DPNP (MFI of 214 vs 113) and were more cytotoxic after 24 hours (IC50: 91.5 nM vs 131.8 nM). 121…”

Section: Examples Of Cuaacmentioning

confidence: 99%

Click and Bioorthogonal Chemistry: The Future of Active Targeting of Nanoparticles for Nanomedicines?

et al. 2021

View full text Add to dashboard Cite

Over the years, click and bioorthogonal reactions have been the subject of considerable research efforts. These high-performance chemical reactions have been developed to meet requirements not often provided by the chemical reactions commonly used today in the biological environment, such as selectivity, rapid reaction rate and biocompatibility. Click and bioorthogonal reactions have been attracting increasing attention in the biomedical field for the engineering of nanomedicines. In this review, we study a compilation of articles from 2014 to the present, using the terms "click chemistry and nanoparticles (NPs)" to highlight the application of this type of chemistry for applications involving NPs intended for biomedical applications. This study identifies the main strategies offered by click and bioorthogonal chemistry, with respect to passive and active targeting, for NP functionalization with specific and multiple properties for imaging and cancer therapy. In the final part, a novel and promising approach for "two step" targeting of NPs, called pretargeting (PT), is also discussed; the principle of this strategy as well as all the studies listed from 2014 to the present are presented in more detail.

show abstract

“…MNPs are a type of MRI contrast agents with multifunctional properties that are considered interesting probes for their co-localization in specific tissues, such as some tumors. Guldris and co-workers [ 56 , 57 , 58 ] and Keasberry et al [ 59 ] reported that proper designs of iron oxide MNPs can significantly enhance the diagnostic capability of MRI when compared to other nanostructured Fe-based contrast agents currently available. The most common magnetic labels used in vivo are based on gadolinium (Gd) complexes and iron oxide magnetic nanoparticles (Fe 3 O 4 ).…”

Section: Magnetic Nanoparticlesmentioning

confidence: 99%

Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cancer is currently a leading cause of death worldwide. The World Health Organization estimates an increase of 60% in the global cancer incidence in the next two decades. The inefficiency of the currently available therapies has prompted an urgent effort to develop new strategies that enable early diagnosis and improve response to treatment. Nanomedicine formulations can improve the pharmacokinetics and pharmacodynamics of conventional therapies and result in optimized cancer treatments. In particular, theranostic formulations aim at addressing the high heterogeneity of tumors and metastases by integrating imaging properties that enable a non-invasive and quantitative assessment of tumor targeting efficiency, drug delivery, and eventually the monitoring of the response to treatment. However, in order to exploit their full potential, the promising results observed in preclinical stages need to achieve clinical translation. Despite the significant number of available functionalization strategies, targeting efficiency is currently one of the major limitations of advanced nanomedicines in the oncology area, highlighting the need for more efficient nanoformulation designs that provide them with selectivity for precise cancer types and tumoral tissue. Under this current need, this review provides an overview of the strategies currently applied in the cancer theranostics field using magnetic nanoparticles (MNPs) and solid lipid nanoparticles (SLNs), where both nanocarriers have recently entered the clinical trials stage. The integration of these formulations into magnetic solid lipid nanoparticles—with different composition and phenotypic activity—constitutes a new generation of theranostic nanomedicines with great potential for the selective, controlled, and safe delivery of chemotherapy.

show abstract

Orthogonal Clickable Iron Oxide Nanoparticle Platform for Targeting, Imaging, and On‐Demand Release

Cited by 15 publications

References 50 publications

Triggering antitumoural drug release and gene expression by magnetic hyperthermia

Triggering antitumoural drug release and gene expression by magnetic hyperthermia

Click and Bioorthogonal Chemistry: The Future of Active Targeting of Nanoparticles for Nanomedicines?

Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics

Contact Info

Product

Resources

About